Identify biomarkers to pair patients with targeted therapies.1-3
Multiple liquid CDx FDA approvals for NSCLC, now with the only FDA-approved CDx for targeted breast cancer therapy in ESR1 mutations.1-3
CDx, companion diagnostic; NSCLC, non-small cell lung cancer.
*The efficacy of TAGRISSO® (osimertinib) has not been established in the EGFR T790M plasma-positive, tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore, testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.¹
TAGRISSO® is a registered trademark of the AstraZeneca group of companies.6
RYBREVANT® is a registered trademark of Janssen Biotech, Inc.7
ENHERTU® is a registered trademark of Daiichi Sankyo Company, Limited.8
LUMAKRAS™ is a trademark of Amgen Inc.9
ORSERDU™ is a trademark of Stemline Therapeutics, a Menarini Group Company.5
Home Guardant Infinity™ for HCPs Treatment Selection Monitoring and MRD Assessment Guardant Infinity™ for BioPharma